Background: The breast cancer takes the first place among women cancer diagnosed worldwide.
Objective: Based on the preferential multi-targeted approach on cancer therapy, we, in this study, aimed to design in silico
drug candidates possessing multi-targeted bioactivity to cope with multi-drug resistance using the known drug structures,
molecular modeling, and ADME parameters.
Methods: We first evaluated the bioactivity score of the approved breast cancer drugs across the top-three drug targets
GPCR, kinase, and nuclear receptors and calculated their physico-chemical properties to see their drug-likeness profiles.
Among 29 approved drugs, Aromasin and Capecitabine showed the broadest bioactivity across the targets listed. By using
molecular modeling and bioisosteric modifications, and applying two filtering approaches, we investigated thirty-one
analogues of Aromasin and Capecitabine.
Results: Software prediction resulted in that the compounds A14, C4, and C13 replaced with B(OH)2 and/or Si(CH3)3
showed a broader spectrum of biological activity with a multi-targeted manner than even the approved analogs.
Conclusion: The interesting point of these new design molecules is to have either silicon and/or boron incorporation. The
increased bioactivity effect of Silicon and Boron incorporation is also seen in the recent approved drug list of FDA and in
clinical trials ongoing. Our new design boron and silicon based molecules appeared to be promising candidates for breast
cancer treatment to be tested in vitro, in vivo, and in clinic for further pharmacological investigations.